Sanofi’s New Pediatric Fitusiran Trial Signals a Long-Term Hemophilia Push
Sanofi SA (SNY) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sanofi Expands Pediatric Hemophilia Bet With New Fitusiran Phase 3 Study
The study called “An Open-label, Parallel, Phase 3, Two-arm Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B” tests fitusiran in young boys. It aims to show that regular preventive treatment can cut bleeding events and improve long term care in severe hemophilia, a key growth area for Sanofi.
The main treatment is fitusiran, also known as SAR439774 or Qfitlia, given as a shot under the skin. It is designed to lower antithrombin and help the body form clots more easily, reducing the need for frequent clotting factor infusions or bypassing drugs.
The study has two arms. One arm enrolls children who have never used fitusiran and another arm rolls over children already on fitusiran from an earlier dose study, with all participants receiving active treatment.
There is no random assignment to different drugs and no placebo group, so all children know they are on fitusiran. The main goal is to test how well the drug prevents bleeds and how safe it is over months of use in regular clinical practice like conditions.
The trial started after the first submission date of December 9, 2025, marking Sanofi’s push into broader pediatric use. The most recent update on February 22, 2026, shows the study is active and still shaping the expected primary and final completion timelines that will drive future filings.
As a Phase 3 study in a younger group, this update supports Sanofi’s strategy to build a full life cycle profile for fitusiran across ages. Success here could support durable revenue, improve sentiment around SNY, and sharpen competition versus other hemophilia options from players like Roche and CSL.
Investors should see the ongoing recruitment status as a sign of continued commitment but not a near term catalyst, since data will come later. The market will watch safety closely, as any safety issues could pressure the stock, while clean data could strengthen Sanofi’s position in long acting hemophilia care.
This Sanofi study is currently recruiting and remains active, with more detailed information and updates available on the ClinicalTrials.gov portal under the listed identifier.
To learn more about SNY’s potential, visit the Sanofi SA drug pipeline page.
